17α-Acyloxy-5β-pregnanes (I) and 17α-acyloxy-5α-pregnanes (IV) have an excellent activity split providing high topical anti-inflammatory activity with very low systemic side effects.
|
1. A 5β-steroid of the formula ##STR1## where R2 is a hydrogen, fluorine or chlorine atom or methyl group;
R6 is a hydrogen, fluorine or chlorine atom or methyl group; R7 is a hydrogen, fluorine or chlorine atom; R9 is a hydrogen, fluorine or chlorine atom; R11 is a chlorine or oxygen atom or hydroxyl group; when R11 is a chlorine atom or hydroxyl group the between R11 and C11 is a single bond in the β configuration and when R11 is an oxygen atom the between R11 and C11 is a double bond; R16α is a hydrogen, fluorine or chlorine atom or methyl group; R16β is a hydrogen atom or methyl group with the proviso that one of R16α or R16β is a hydrogen atom; R17 is alkyl of 1 through 6 carbon atoms, phenyl, p-methylphenyl, p-carboxyphenyl or p-carboalkoxyphenyl; R21 is a hydrogen, fluorine, chlorine or bromine atom or a --OR21α or --OSO2 CH3 group; R21α is a hydrogen atom, --COR21β or --PO(OH)2 and pharmaceutically acceptable salts thereof; R21β is alkyl of 1 through 6 carbon atoms, phenyl, p-methylphenyl, or p-carboxyphenyl, p-carboalkoxyphenyl, --CH2 CH2 COOH and pharmaceutically acceptable salts thereof; is a single or double bond; and indicates the attached group can be in either the α or β configuration.
11. A compound according to
13. A compound according to
14. A compound according to
15. A compound according to
|
This is a division of application Ser. No. 117,401, filed Jan. 31, 1980 now U.S. Pat. No. 4,318,853.
The present invention relates to 5α and 5β- 17α-acyloxy corticoids which are useful as topical anti-inflammatory agents for which the essential material constituting a disclosure thereof is incorporated by reference here from U.S. patent application Ser. No. 117,401, filed Jan. 31, 1980, now U.S. Pat. No. 4,318,853.
Ayer, Donald E., Schlagel, Carl A.
Patent | Priority | Assignee | Title |
10000525, | Apr 05 2010 | ReveraGen BioPharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
10206933, | May 28 2008 | ReveraGen BioPharma, Inc. | Non-hormonal steroid modulators of NF-kB for treatment of disease |
10799514, | Jun 29 2015 | ReveraGen BioPharma, Inc. | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease |
10857161, | May 28 2008 | ReveraGen BioPharma, Inc. | Non-hormonal steroid modulators of NF-kB for treatment of disease |
11382922, | Mar 07 2019 | ReveraGen BioPharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
11471471, | Mar 07 2019 | ReveraGen BioPharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
11690853, | Jun 29 2015 | ReveraGen BioPharma, Inc. | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
11833159, | May 28 2008 | ReveraGen BioPharma, Inc. | Non-hormonal steroid modulators of NF-kB for treatment of disease |
8207151, | May 28 2008 | Reveragen Biopharma, Inc | Non-hormonal steroid modulators of NF-κB for treatment of disease |
8334279, | Jul 20 2010 | Validus Genetics | Non-hormonal steroid modulators of NF-κB for treatment of disease |
8673887, | May 28 2008 | Reveragen Biopharma, Inc | Non-hormonal steroid modulators of NF-kB for treatment of disease |
9198921, | Apr 05 2010 | FREERUN TECHNOLOGIES, INC | Non-hormonal steroid modulators of NF-κB for treatment of disease |
9434758, | May 28 2008 | ReveraGen BioPharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
9649320, | May 28 2008 | ReveraGen BioPharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
Patent | Priority | Assignee | Title |
4336200, | Jan 31 1980 | UPJOHN COMPANY THE, A CORP OF DE | 17α-Acyloxy-5β-corticoids |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Sep 03 1981 | The Upjohn Company | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Apr 27 1987 | M170: Payment of Maintenance Fee, 4th Year, PL 96-517. |
Apr 29 1987 | ASPN: Payor Number Assigned. |
Apr 26 1992 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Apr 24 1987 | 4 years fee payment window open |
Oct 24 1987 | 6 months grace period start (w surcharge) |
Apr 24 1988 | patent expiry (for year 4) |
Apr 24 1990 | 2 years to revive unintentionally abandoned end. (for year 4) |
Apr 24 1991 | 8 years fee payment window open |
Oct 24 1991 | 6 months grace period start (w surcharge) |
Apr 24 1992 | patent expiry (for year 8) |
Apr 24 1994 | 2 years to revive unintentionally abandoned end. (for year 8) |
Apr 24 1995 | 12 years fee payment window open |
Oct 24 1995 | 6 months grace period start (w surcharge) |
Apr 24 1996 | patent expiry (for year 12) |
Apr 24 1998 | 2 years to revive unintentionally abandoned end. (for year 12) |